Cementless total hip arthroplasty in young Chinese patients: a comparison of 2 different prostheses

The Journal of Arthroplasty
K Y ChiuK M Lee

Abstract

Sixty-one primary cementless total hip arthroplasties were performed in 45 Chinese patients <40 years old. There were 27 Anatomic Medullary Locking (AML, Depuy, Warsaw, IN) prostheses and 34 Porous Coated Anatomic (PCA, Howmedica, Rutherford, NJ) prostheses. The average follow-up was 7.6 years (range, 3-11 years). Ten hips (16%) were reoperated; the reason was polyethylene wear with or without osteolysis in 7 hips. Osteolytic lesion was present in 34 hips (56%). The cumulative successful rate at 10 years was 67% using reoperation for any reason as the endpoint. The cumulative successful rate was 98%, however, if revision for aseptic loosening was used as the endpoint. The 2 prostheses did not show significant differences in most parameters except that the PCA hips had significantly more acetabular loosening (P =.02) and periprosthetic osteolysis (P =.01).

References

Nov 1, 1978·Clinical Orthopaedics and Related Research·M J GriffithJ Charnley
Sep 1, 1989·The Journal of Arthroplasty·P MassinC A Engh
Jun 1, 1988·Clinical Orthopaedics and Related Research·S H White
Jan 1, 1986·The Journal of Arthroplasty·C S Ranawat, M G Zahn
Sep 1, 1996·The Journal of Arthroplasty·N HyderT G Barabas
Feb 11, 1998·The Journal of Arthroplasty·P A DowdyR B Bourne
Apr 18, 1998·The Journal of Bone and Joint Surgery. British Volume·B M WroblewskiP D Siney
Feb 15, 2001·The Journal of Arthroplasty·K Y ChiuD Yip
Apr 28, 2005·The Journal of Bone and Joint Surgery. British Volume·Y-H Kim
May 25, 2005·The Journal of Bone and Joint Surgery. British Volume·O P P TemmermanI C Heyligers
Mar 3, 2007·The Journal of Bone and Joint Surgery. American Volume·Steven T Woolson, Michael N Kang
Mar 2, 2010·The Journal of Bone and Joint Surgery. British Volume·M J B KeelK A Siebenrock
Nov 8, 2014·The Journal of Bone and Joint Surgery. American Volume·Lucian C WarthRichard C Johnston

❮ Previous
Next ❯

Citations

Jun 20, 2006·The Journal of Arthroplasty·Michael J ArchibeckRichard E White
Mar 27, 2004·Clinical Orthopaedics and Related Research·James P McAuleyCharles A Engh
Mar 12, 2015·Clinical Orthopaedics and Related Research·Eric M PadegimasSurena Namdari
Jul 1, 2015·Clinical Orthopaedics and Related Research·Kevin L GarvinJohn Martell

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.